97 related articles for article (PubMed ID: 34355463)
1. Liquid Biopsy and Radiological Response Predict Outcomes Following Discontinuation of Targeted Therapy in Patients with BRAF Mutated Melanoma.
Di Guardo L; Randon G; Corti F; Vallacchi V; Raimondi A; Fucà G; Bini M; Maurichi A; Patuzzo R; Gallino G; Mattavelli I; Ruggeri R; Angi M; Cossa M; Valeri B; Cimminiello C; Santinami M; Rivoltini L; de Braud F; Rodolfo M; Vecchio MD
Oncologist; 2021 Dec; 26(12):1079-1084. PubMed ID: 34355463
[TBL] [Abstract][Full Text] [Related]
2. The Prognostic Impact of Circulating Tumour DNA in Melanoma Patients Treated with Systemic Therapies-Beyond
Marsavela G; Johansson PA; Pereira MR; McEvoy AC; Reid AL; Robinson C; Warburton L; Khattak MA; Meniawy TM; Amanuel B; Millward M; Hayward NK; Ziman MR; Gray ES; Calapre L
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33339135
[TBL] [Abstract][Full Text] [Related]
3. A multiparameter liquid biopsy approach allows to track melanoma dynamics and identify early treatment resistance.
Scaini MC; Catoni C; Poggiana C; Pigozzo J; Piccin L; Leone K; Scarabello I; Facchinetti A; Menin C; Elefanti L; Pellegrini S; Aleotti V; Vidotto R; Schiavi F; Fabozzi A; Chiarion-Sileni V; Rosato A
NPJ Precis Oncol; 2024 Mar; 8(1):78. PubMed ID: 38548846
[TBL] [Abstract][Full Text] [Related]
4. Detection of
Clark ME; Rizos H; Pereira MR; McEvoy AC; Marsavela G; Calapre L; Meehan K; Ruhen O; Khattak MA; Meniawy TM; Long GV; Carlino MS; Menzies AM; Millward M; Ziman M; Gray ES
Oncotarget; 2020 Nov; 11(44):4016-4027. PubMed ID: 33216826
[TBL] [Abstract][Full Text] [Related]
5. Corrigendum to "Sustained release hydrogel for durable locoregional chemoimmunotherapy for BRAF-mutated melanoma" [Journal of Controlled Release 357 (2023) 655-668].
Kim J; Archer PA; Manspeaker MP; Avecilla ARC; Pollack BP; Thomas SN
J Control Release; 2024 Feb; 366():834-837. PubMed ID: 38290359
[No Abstract] [Full Text] [Related]
6. The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients.
Zaremba A; Eggermont AMM; Robert C; Dummer R; Ugurel S; Livingstone E; Ascierto PA; Long GV; Schadendorf D; Zimmer L
Eur J Cancer; 2021 Sep; 155():268-280. PubMed ID: 34392069
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival.
Mandala M; Larkin J; Ascierto PA; Del Vecchio M; Gogas H; Cowey CL; Arance A; Dalle S; Schenker M; Grob JJ; Chiarion-Sileni V; Marquez-Rodas I; Butler MO; Di Giacomo AM; Lutzky J; De La Cruz-Merino L; Atkinson V; Arenberger P; Hill A; Fecher L; Millward M; Khushalani NI; de Pril V; Lobo M; Weber J
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34452930
[TBL] [Abstract][Full Text] [Related]
8. Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases.
Hilbers ML; Dimitriou F; Lau P; Bhave P; McArthur GA; Zimmer L; Kudura K; Gérard CL; Levesque MP; Michielin O; Dummer R; Cheng PF; Mangana J
Eur J Cancer; 2021 Oct; 156():149-163. PubMed ID: 34454317
[TBL] [Abstract][Full Text] [Related]
9. Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy.
Bai X; Hu J; Betof Warner A; Quach HT; Cann CG; Zhang MZ; Si L; Tang B; Cui C; Yang X; Wei X; Pallan L; Harvey C; Manos MP; Ouyang O; Kim MS; Kasumova G; Cohen JV; Lawrence DP; Freedman C; Fadden RM; Rubin KM; Sharova T; Frederick DT; Flaherty KT; Rahma OE; Long GV; Menzies AM; Guo J; Shoushtari AN; Johnson DB; Sullivan RJ; Boland GM
Clin Cancer Res; 2021 Nov; 27(21):5993-6000. PubMed ID: 34376536
[TBL] [Abstract][Full Text] [Related]
10. The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma.
Ny L; Jespersen H; Karlsson J; Alsén S; Filges S; All-Eriksson C; Andersson B; Carneiro A; Helgadottir H; Levin M; Ljuslinder I; Olofsson Bagge R; Sah VR; Stierner U; Ståhlberg A; Ullenhag G; Nilsson LM; Nilsson JA
Nat Commun; 2021 Aug; 12(1):5155. PubMed ID: 34453044
[TBL] [Abstract][Full Text] [Related]
11. Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors.
Arangalage D; Degrauwe N; Michielin O; Monney P; Özdemir BC
Cancer Treat Rev; 2021 Nov; 100():102282. PubMed ID: 34438238
[TBL] [Abstract][Full Text] [Related]
12. Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy.
Wang Y; Liu S; Yang Z; Algazi AP; Lomeli SH; Wang Y; Othus M; Hong A; Wang X; Randolph CE; Jones AM; Bosenberg MW; Byrum SD; Tackett AJ; Lopez H; Yates C; Solit DB; Ribas A; Piva M; Moriceau G; Lo RS
Cancer Cell; 2021 Oct; 39(10):1375-1387.e6. PubMed ID: 34416167
[TBL] [Abstract][Full Text] [Related]
13. Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial.
Martinelli E; Martini G; Famiglietti V; Troiani T; Napolitano S; Pietrantonio F; Ciardiello D; Terminiello M; Borrelli C; Vitiello PP; De Braud F; Morano F; Avallone A; Normanno N; Nappi A; Maiello E; Latiano T; Falcone A; Cremolini C; Rossini D; Santabarbara G; Pinto C; Santini D; Cardone C; Zanaletti N; Di Liello A; Renato D; Esposito L; Marrone F; Ciardiello F
JAMA Oncol; 2021 Oct; 7(10):1529-1535. PubMed ID: 34382998
[TBL] [Abstract][Full Text] [Related]
14. Detection of clinical progression through plasma ctDNA in metastatic melanoma patients: a comparison to radiological progression.
Marsavela G; McEvoy AC; Pereira MR; Reid AL; Al-Ogaili Z; Warburton L; Khattak MA; Abed A; Meniawy TM; Millward M; Ziman MR; Calapre L; Gray ES
Br J Cancer; 2022 Feb; 126(3):401-408. PubMed ID: 34373567
[TBL] [Abstract][Full Text] [Related]
15. NGS Analysis of Liquid Biopsy (LB) and Formalin-Fixed Paraffin-Embedded (FFPE) Melanoma Samples Using Oncomine™ Pan-Cancer Cell-Free Assay.
Olbryt M; Rajczykowski M; Bal W; Fiszer-Kierzkowska A; Cortez AJ; Mazur M; Suwiński R; Widłak W
Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356096
[TBL] [Abstract][Full Text] [Related]
16. Characterization and management of neurological adverse events during immune-checkpoint inhibitors treatment: an Italian multicentric experience.
Diamanti L; Picca A; Bini P; Gastaldi M; Alfonsi E; Pichiecchio A; Rota E; Rudà R; Bruno F; Villani V; Galiè E; Vogrig A; Valente M; Zoccarato M; Poretto V; Giometto B; Cimminiello C; Del Vecchio M; Marchioni E
Neurol Sci; 2022 Mar; 43(3):2031-2041. PubMed ID: 34424427
[TBL] [Abstract][Full Text] [Related]
17. Exploratory analysis of clinical benefit of ipilimumab and nivolumab treatment in patients with metastatic melanoma from a single institution.
Vila CM; Moreno FA; Estébanez MM; Ares GR; Villacampa G; Dashti P; Oberoi HS; Martin-Huertas R; Jares P; Alos L; Teixido C; Rull R; Sanchez M; Malvehy J; Carcelero E; Valduvieco I; Fernandez AA
Clin Transl Oncol; 2022 Feb; 24(2):319-330. PubMed ID: 34420138
[TBL] [Abstract][Full Text] [Related]
18. TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma.
Hodi FS; Wolchok JD; Schadendorf D; Larkin J; Long GV; Qian X; Saci A; Young TC; Srinivasan S; Chang H; Tang H; Wind-Rotolo M; Rizzo JI; Jackson DG; Ascierto PA
Cancer Immunol Res; 2021 Oct; 9(10):1202-1213. PubMed ID: 34389558
[TBL] [Abstract][Full Text] [Related]
19. KEAP1/NFE2L2 Mutations of Liquid Biopsy as Prognostic Biomarkers in Patients With Advanced Non-Small Cell Lung Cancer: Results From Two Multicenter, Randomized Clinical Trials.
Zhu H; Xie D; Yu Y; Yao L; Xu B; Huang L; Wu S; Li F; Zheng Y; Liu X; Xie W; Huang M; Li H; Zheng S; Zhang D; Qiao G; Chan LWC; Zhou H
Front Oncol; 2021; 11():659200. PubMed ID: 34381706
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
